Nuvation Bio Inc
NUVB_t0.307USD
-0.023-6.85%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Nuvation Bio Inc Company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Nuvation Bio Inc Info
Ticker SymbolNUVB_t
Company nameNuvation Bio Inc
IPO dateJul 01, 2020
CEODr. David T. Hung, M.D.
Number of employees- -
Security type- -
Fiscal year-end- -
Address357 Tehama Street, Floor 3
CitySAN FRANCISCO
Stock exchange- -
CountryUnited States of America
Postal code94103
Phone14157543517
Websitehttps://www.nuvationbio.com/
Ticker SymbolNUVB_t
IPO dateJul 01, 2020
CEODr. David T. Hung, M.D.
Company Executives of Nuvation Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
--
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
--
--
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
4.12M
0.00%
-604.94K
2025Q3
32
4.10M
0.00%
-28.02M
2025Q2
30
31.59M
0.00%
+26.34M
2025Q1
30
31.74M
0.00%
+26.49M
2024Q4
31
4.90M
0.00%
-302.14K
2024Q3
30
4.86M
0.00%
-182.30K
2024Q2
31
4.71M
0.00%
+261.45K
2024Q1
29
4.01M
0.00%
-276.84K
2023Q4
27
4.00M
0.00%
-301.37K
2023Q3
26
4.18M
0.00%
-276.64K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rock Springs Capital Management LP
134.03K
0%
--
--
Sep 30, 2025
Samsara BioCapital, LLC
133.33K
0%
--
--
Sep 30, 2025
Greenlight Capital, Inc.
100.00K
0%
--
--
Sep 30, 2025
Acuta Capital Partners, LLC
90.83K
0%
--
--
Sep 30, 2025
Citadel Advisors LLC
73.42K
0%
-125.00
-0.17%
Sep 30, 2025
Logos Global Management LP
66.67K
0%
--
--
Sep 30, 2025
Victory Capital Management Inc.
20.38K
0%
--
--
Sep 30, 2025
Intellectus Partners, LLC
26.40K
0%
+4.00K
+17.86%
Sep 30, 2025
Wolverine Asset Management, LLC
36.16K
0%
+36.16K
--
Sep 30, 2025
Boxer Capital Management, LLC
266.67K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Nuvation Bio Inc?
The top five shareholders of Nuvation Bio Inc are:
Rock Springs Capital Management LP holds 134.03K shares, accounting for 0.00% of the total shares.
Samsara BioCapital, LLC holds 133.33K shares, accounting for 0.00% of the total shares.
Greenlight Capital, Inc. holds 100.00K shares, accounting for 0.00% of the total shares.
Acuta Capital Partners, LLC holds 90.83K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 73.42K shares, accounting for 0.00% of the total shares.
Rock Springs Capital Management LP holds 134.03K shares, accounting for 0.00% of the total shares.
Samsara BioCapital, LLC holds 133.33K shares, accounting for 0.00% of the total shares.
Greenlight Capital, Inc. holds 100.00K shares, accounting for 0.00% of the total shares.
Acuta Capital Partners, LLC holds 90.83K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 73.42K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Nuvation Bio Inc?
The top three shareholder types of Nuvation Bio Inc are:
Other
Other
How many institutions hold shares of Nuvation Bio Inc (NUVB_t)?
As of 2025Q4, 31 institutions hold shares of Nuvation Bio Inc, with a combined market value of approximately 4.12M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Nuvation Bio Inc?
In --, the -- business generated the highest revenue for Nuvation Bio Inc, amounting to -- and accounting for --% of total revenue.
